Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Hoffman WilliamOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-200Price:$43.61
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Hoffman WilliamOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,491Price:$42.73
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Hoffman WilliamOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-35,858Price:$41.94
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Warner Robert KeithOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Szyman Catherine M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Root Jonathan DOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Milder Donald BOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Mead Dana G Jr.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Lucchese Cynthia LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Hoffman WilliamOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
Filings by filing date
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Hoffman WilliamOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-200Price:$43.61
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Hoffman WilliamOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,491Price:$42.73
-
May 01, 2024 (filed on May 03, 2024)Insider Name:Hoffman WilliamOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-35,858Price:$41.94
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Warner Robert KeithOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Szyman Catherine M.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Root Jonathan DOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Milder Donald BOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Mead Dana G Jr.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Lucchese Cynthia LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
-
Apr 24, 2024 (filed on Apr 26, 2024)Insider Name:Hoffman WilliamOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,126Price:$42.41
News
Biz Brief
Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 6001 Oak Canyon, Suite 100 IRVINE CA 92618 |
Tel: | N/A |
Website: | https://www.inarimedical.com |
IR: | See website |
Key People | ||
Andrew Hykes President, Chief Executive Officer, Director | Mitchell C. Hill Chief Financial Officer | Thomas Tu Chief Medical Officer |
Business Overview |
Inari Medical, Inc. is a medical device company. The Company's products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss. |
Financial Overview |
For the three months ended 31 March 2024, Inari Medical Inc revenues increased 23% to $143.2M. Net loss increased from $2.2M to $24.2M. Revenues reflect United States segment increase of 20% to $133.7M, International segment increase from $4.3M to $9.5M. Higher net loss reflects Selling, general and administrative - Ba increase of 20% to $91.4M (expense), Research and development increase of 23% to $25.1M (expense). |
Employees: | 1,300 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $2,331M as of Mar 31, 2024 |
Annual revenue (TTM): | $520.66M as of Mar 31, 2024 |
EBITDA (TTM): | -$13.69M as of Mar 31, 2024 |
Net annual income (TTM): | -$23.62M as of Mar 31, 2024 |
Free cash flow (TTM): | $18.51M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 58,138,159 as of Apr 26, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |